Wongi Seol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wongi Seol has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Hye Jin Yun
Institute for Brain Science and Technology, Inje University, 633-146, Gaegumdong, Busanjingu, Busan 614-735, Republic of Korea
2 shared publicationsBong-Su Kang
Juseong Gene Therapy R&D Center, Department of Biotechnology, Juseong College, Chungbuk 363-794, Korea
1 shared publicationHye Young Heo
Institute for Brain Science and Technology, Inje University, Busan 633-146, Korea
1 shared publicationHye-Kyoung Yoon
Department of Pathology, Inje Medical School, Busan 614-735, Korea
1 shared publicationHyerhan Jeong
Institute for Brain Science and Technology, Inje University, Daejeon, South Korea
1 shared publication- Hyunha Kim
Department of Korean Medical Science, School of Korean Medicine, Pusan National University, Yangsan, Gyeongnam 50612, Republic of Korea
1 shared publication
Latest Publications
- 30 April 2011
- Published by Korean Society of Life Science in Journal of Life Science
- Vol. 21 (4) , 481-485
T0901317 as an Inhibitor of Transcriptional Activation of Constitutive Androstane Receptor (CAR)
- 30 April 2011
- Published by Korean Society of Life Science in Journal of Life Science
- Vol. 21 (4) , 481-485
T0901317 as an Inhibitor of Transcriptional Activation of Constitutive Androstane Receptor (CAR)
- Open Access
- 30 September 2010
- Published by The Korean Society for Brain and Neural Science in Experimental Neurobiology
- Vol. 19 (2) , 97-105
Coordinate Regulation of Neurite Outgrowth by LRRK2 and Its Interactor, Rab5
Heo HY, et al. Exp Neurobiol. 2010 Sep;19(2):97-105. http://dx.doi.org/10.5607/en.2010.19.2.97
- 30 September 2010
- Published by The Korean Society for Brain and Neural Science in Experimental Neurobiology
- Vol. 19 (2) , 97-105
Open AccessCoordinate Regulation of Neurite Outgrowth by LRRK2 and Its Interactor, Rab5
Heo HY, et al. Exp Neurobiol. 2010 Sep;19(2):97-105. http://dx.doi.org/10.5607/en.2010.19.2.97
- Open Access
- 30 April 2010
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 43 (4) , 233-244
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease GTPase;G2019S;Kinase;LRRK2;Parkinson's disease; Parkinson's disease (PD) is the second most common neurodegenerative disease, and 5-10% of the PD cases are genetically inherited as familial PD (FPD). LRRK2 (leucine-rich repeat kinase 2) was first reported in 2004 as a gene corresponding to PARK8, an autosomal gene whose dominant mutations cause familial PD. LRRK2 contains both active kinase and GTPase domains as well as protein-protein interaction motifs such as LRR (leucine-rich repeat) and WD40. Most pathogenic LRRK2 mutations are located in either the GTPase or kinase domain, implying important roles for the enzymatic activities in PD pathogenic mechanisms. In comparison to other PD causative genes such as parkin and PINK1, LRRK2 exhibits two important features. One is that LRRK2's mutations (especially the G2019S mutation) were observed in sporadic as well as familial PD patients. Another is that, among the various PD-causing genes, pathological characteristics observed in patients carrying LRRK2 mutations are the most similar to patients with sporadic PD. Because of these two observations, LRRK2 has been intensively investigated for its pathogenic mechanism (s) and as a target gene for PD therapeutics. In this review, the general biochemical and molecular features of LRRK2, the recent results of LRRK2 studies and LRRK2's therapeutic potential as a PD target gene will be discussed.
- 30 April 2010
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 43 (4) , 233-244
Open AccessBiochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease GTPase;G2019S;Kinase;LRRK2;Parkinson's disease; Parkinson's disease (PD) is the second most common neurodegenerative disease, and 5-10% of the PD cases are genetically inherited as familial PD (FPD). LRRK2 (leucine-rich repeat kinase 2) was first reported in 2004 as a gene corresponding to PARK8, an autosomal gene whose dominant mutations cause familial PD. LRRK2 contains both active kinase and GTPase domains as well as protein-protein interaction motifs such as LRR (leucine-rich repeat) and WD40. Most pathogenic LRRK2 mutations are located in either the GTPase or kinase domain, implying important roles for the enzymatic activities in PD pathogenic mechanisms. In comparison to other PD causative genes such as parkin and PINK1, LRRK2 exhibits two important features. One is that LRRK2's mutations (especially the G2019S mutation) were observed in sporadic as well as familial PD patients. Another is that, among the various PD-causing genes, pathological characteristics observed in patients carrying LRRK2 mutations are the most similar to patients with sporadic PD. Because of these two observations, LRRK2 has been intensively investigated for its pathogenic mechanism (s) and as a target gene for PD therapeutics. In this review, the general biochemical and molecular features of LRRK2, the recent results of LRRK2 studies and LRRK2's therapeutic potential as a PD target gene will be discussed.
- 19 August 2008
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 389 (10) , 1313-1318
Specific inhibition of transcriptional activity of the constitutive androstane receptor (CAR) by the splicing factor SF3a3
The constitutive androstane receptor (CAR) is a member of the nuclear receptor superfamily and plays an important role in the degradation of xenobiotics in the liver. Using yeast two-hybrid screening, we identified SF3a3, a 60-kDa subunit of the splicing factor 3a complex, as a specific CAR-interacting protein. We further confirmed their interaction by both co-immunoprecipitation and GST pull-down assay. Functional studies showed that overexpression of SF3a3 inhibited the reporter activity driven by a promoter containing CAR binding sequences by up to 50%, whereas reduced expression of SF3a3 activated the same reporter activity by approximately three-fold. The inhibitory function of SF3a3 is independent of the presence of TCPOBOP, a CAR ligand. These data suggest that SF3a3 functions as a co-repressor of CAR transcriptional activity, in addition to its canonical function.
- 19 August 2008
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 389 (10) , 1313-1318
Specific inhibition of transcriptional activity of the constitutive androstane receptor (CAR) by the splicing factor SF3a3
The constitutive androstane receptor (CAR) is a member of the nuclear receptor superfamily and plays an important role in the degradation of xenobiotics in the liver. Using yeast two-hybrid screening, we identified SF3a3, a 60-kDa subunit of the splicing factor 3a complex, as a specific CAR-interacting protein. We further confirmed their interaction by both co-immunoprecipitation and GST pull-down assay. Functional studies showed that overexpression of SF3a3 inhibited the reporter activity driven by a promoter containing CAR binding sequences by up to 50%, whereas reduced expression of SF3a3 activated the same reporter activity by approximately three-fold. The inhibitory function of SF3a3 is independent of the presence of TCPOBOP, a CAR ligand. These data suggest that SF3a3 functions as a co-repressor of CAR transcriptional activity, in addition to its canonical function.
- Open Access
- 1 January 2008
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 40 (3) , 345-353
Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2
Experimental & Molecular Medicine is an open access journal that publishes the highest quality articles in translational research and biomedical studies.
- 1 January 2008
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 40 (3) , 345-353
Open AccessTranscriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2
Experimental & Molecular Medicine is an open access journal that publishes the highest quality articles in translational research and biomedical studies.
- 12 May 2006
- Published by Wiley in Journal of Neurochemistry
- Vol. 98 (2) , 386-394
Regulation of tyrosine hydroxylase gene expression by retinoic acid receptor
Retinoic acid (RA), a derivative of vitamin A, critically controls brain patterning and neurogenesis during embryogenesis, and is known to regulate morphological differentiation of catecholaminergic neuronal cells. In this study, we investigated whether the retinoic acid receptor (RAR), a transcription factor specifically activated by all‐trans‐RA, could directly regulate transcription of tyrosine hydroxylase (TH), the first and rate‐limiting step in the catecholamine biosynthesis pathway. First, treating TH‐expressing human neuroblastoma SK‐N‐BE(2)C cells with all‐trans RA resulted in an approximately 1.7‐fold increase in endogenous TH mRNA expression, as determined by real‐time PCR analysis. Second, when SK‐N‐BE(2)C cells were transiently co‐transfected with the TH promoter‐luciferase reporter construct, reporter gene expression was prominently activated by RAR in a ligand‐dependent manner. Third, we identified a putative RAR responsive cis‐regulatory element at − 1500 to − 1487 bp in the TH upstream promoter region by deletional and site‐directed mutational analysis. Finally, we demonstrated that this putative motif directly interacts with RAR protein in a sequence‐specific manner by means of an electrophoretic mobility shift assay. Taken together, our results indicate that the TH gene may be a direct downstream target of the RA signaling pathway and that RAR is able to activate TH transcription through interaction with an upstream sequence motif residing at − 1500 to − 1487 bp.
- 12 May 2006
- Published by Wiley in Journal of Neurochemistry
- Vol. 98 (2) , 386-394
Regulation of tyrosine hydroxylase gene expression by retinoic acid receptor
Retinoic acid (RA), a derivative of vitamin A, critically controls brain patterning and neurogenesis during embryogenesis, and is known to regulate morphological differentiation of catecholaminergic neuronal cells. In this study, we investigated whether the retinoic acid receptor (RAR), a transcription factor specifically activated by all‐trans‐RA, could directly regulate transcription of tyrosine hydroxylase (TH), the first and rate‐limiting step in the catecholamine biosynthesis pathway. First, treating TH‐expressing human neuroblastoma SK‐N‐BE(2)C cells with all‐trans RA resulted in an approximately 1.7‐fold increase in endogenous TH mRNA expression, as determined by real‐time PCR analysis. Second, when SK‐N‐BE(2)C cells were transiently co‐transfected with the TH promoter‐luciferase reporter construct, reporter gene expression was prominently activated by RAR in a ligand‐dependent manner. Third, we identified a putative RAR responsive cis‐regulatory element at − 1500 to − 1487 bp in the TH upstream promoter region by deletional and site‐directed mutational analysis. Finally, we demonstrated that this putative motif directly interacts with RAR protein in a sequence‐specific manner by means of an electrophoretic mobility shift assay. Taken together, our results indicate that the TH gene may be a direct downstream target of the RA signaling pathway and that RAR is able to activate TH transcription through interaction with an upstream sequence motif residing at − 1500 to − 1487 bp.